Publications by authors named "N Izawa"
Aim: To evaluate the feasibility and safety of total neoadjuvant therapy with long-course chemoradiotherapy followed by consolidation chemotherapy in Japanese patients with locally advanced rectal cancer.
Methods: This prospective, multicenter, single-arm, phase II trial was conducted at 10 centers. The eligibility criteria included age ≥20 y, locally advanced rectal cancer within 12 cm of the anal verge, and cT3-4N0M or TanyN+M0 at diagnosis, enabling curative resection.
Purpose: Opioid-induced constipation is the most frequent and non-self-limiting adverse effect of opioid analgesia, reducing adherence and interfering with pain relief. This clinical trial aimed to clarify the preventive effect of naldemedine versus placebo for constipation in patients with cancer starting regularly dosed strong opioids therapy.
Methods: This multicenter, double-blinded, randomized, placebo-controlled, confirmatory trial was conducted between July 2021 and May 2023 at four academic hospitals in Japan (Japan Registry of Clinical Trials identifier: jRCTs031200397).
Article Synopsis
- This study analyzes real-world data from a comprehensive genomic profiling (CGP) of 1,364 patients with advanced small intestine cancer, focusing on identifying clinically relevant genetic alterations across different patient subgroups based on age and molecular characteristics.
- Key findings reveal that patients under 40 have a significantly lower rate of certain mutations compared to older patients, and 22.3% of the cohort had mutations that could be targeted by existing therapies.
- The results contribute to a better understanding of the genetic landscape of small intestine cancer, which may help guide future treatment strategies.
Article Synopsis
- The study evaluated the effectiveness of definitive chemoradiotherapy (dCRT) as a method to preserve organs in patients with esophageal squamous cell carcinoma (ESCC) who showed a significant response to induction chemotherapy.
- Eligible patients received 3 cycles of a chemotherapy regimen followed by dCRT if they were downstaged to stage IA, with the main goal of achieving high 1-year progression-free survival rates.
- Results showed that 58.4% of patients had a remarkable response, with 89.8% achieving complete response after dCRT; the study reported a 1-year progression-free survival of 89.8% and a 3-year overall survival of 83.7% during follow-up.